Quick Answer
Sanofi reported R&D Expense of $7.84 billion for fiscal year 2025.
Sanofi R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.84B | +6.1% |
| 2024 | $7.39B | +13.6% |
| 2023 | $6.51B | +0.1% |
| 2022 | $6.50B | +14.2% |
| 2021 | $5.69B | +2.9% |
| 2020 | $5.53B | -8.1% |
| 2019 | $6.02B | +2.1% |
| 2018 | $5.89B | +7.7% |
| 2017 | $5.47B | +5.8% |
| 2016 | $5.17B | — |
- Sanofi showed an increase of +6.1% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Sanofi’s r&d expense has grown by 51.6% (from $5.17 billion to $7.84 billion).
- The most recent figure is from Sanofi’s fiscal year 2025 report (Form 20-F), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: